Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination.
This is a study of immune responses generated by mutant ras peptide vaccination of patients with pancreatic adenocarcinoma. Responding T cells from one patient were cloned and two CD4+ T-lymphocyte clones (TLC) specific for the 12 Val peptide and restricted by HLA-DR6 or DQ2 were obtained. These class II molecules have not previously been found to bind or present mutant ras peptides to T cells. The DR6-restricted TLC showed marked cytotoxicity against autologous target cells pulsed with the 12 Val peptide. Target cells pulsed with the control peptide were not killed. Responding T cells from another patient showed cross-reactivity towards the homologous ras peptides. Investigation by limiting dilution analysis (LDA) revealed different T-cell precursor frequencies for the immunising, mutant ras peptide (1:28000), compared with the normal ras peptide (1:110000).
Gjertsen
M K
MK
Institute of Transplantation Immunology, National Hospital, University of Oslo, Norway.
Saeterdal
I
I
Thorsby
E
E
Gaudernack
G
G
D001402:B-Lymphocytes / Q000276:immunology / Q000821:virology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D002461:Cell Line, Transformed; D003429:Cross Reactions / Q000276:immunology; D004854:Herpesvirus 4, Human; D006801:Humans; D007111:Immunity, Cellular; D008297:Male; D008875:Middle Aged; D015689:Oncogene Protein p21(ras) / Q000235:genetics / Q000276:immunology*; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000276:immunology*; D014611:Vaccination
D015689:Oncogene Protein p21(ras)